Health Care • Medical/Dental Instruments
$9.94 ▼ -0.21
(-2.07%)
MKT CAP: $66.0M • VOL: 75.3K
52W L $10 52W H $35
SKIN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $300.8M | $334.3M | $398.0M |
| YoY Revenue Growth % | -10.0% | -16.0% | — |
| Gross Profit | $196.4M | $182.3M | — |
| Gross Margin % | 65.3% | 54.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.8M | -$67.8M | -$130.9M |
| Operating Margin % | -6.9% | -20.3% | -32.9% |
| Net Income (GAAP) | -$9.5M | -$29.1M | -$100.1M |
| EBITDA (Normalized) | -$20.6M | -$67.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $37.5M | $16.1M | $21.8M |
| Capital Expenditures (CapEx) | $303.0K | $756.0K | — |
| Free Cash Flow (FCF) | $37.2M | $15.4M | $21.8M |
| FCF Margin % | 12.4% | 4.6% | 5.5% |
| Return on Invested Capital (ROIC %) | -26.9% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $61.1M | $51.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SKIN.